Page 36 - Read Online

ROLE OF BILE ACIDS IN FXR-MEDIATED Financial support and sponsorship
INHIBITION OF TUMORIGENESIS Nil.

Colon cancer is often linked to a Western diet, rich Conflicts of interest
in carbohydrates and saturated fatty acids. [42-44] Subjects There are no conflicts of interest.
who consume a Western diet and patients with CRC
have elevated levels of fecal secondary bile acids, REFERENCES
mostly lithocholic acid (LCA) and deoxycholic acid
(DCA), implicating bile acids as contributing factors 1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R,
in colon carcinogenesis. [45-48] Although controversial, Waldron W, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H,
cholecystectomy, which increases intestinal bile acid Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K, Edwards
B. SEER Cancer Statistics Review, 1975-2008, Bethesda, MD:
levels, may predispose persons to CRC. [49,50] Nonetheless, national Cancer Institute. Based on November 2010 SEER Data
recent evidence suggests that FXR inhibits intestinal Submission, Posted to the SEER; 2011. Available from: http://www.
tumorigenesis through a bile acid-independent mechanism. seer.cancer.gov/csr/1975-2008/. [Last accessed on 2015 Jul 20].
Degirolamo et al. showed that FXR deficiency, not 2. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE,
[51]
elevated bile acid levels, mediated susceptibility to Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan
intestinal tumorigenesis. The tumor-promoting activity of DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen
JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden
bile acids does not occur as a function of their ability to of gastrointestinal disease in the United States: 2012 update.
activate FXR in the intestines. [29,51] Raufman et al. showed Gastroenterology 2012;143:1179-87e1-3.
that several bile acids, including DCA and LCA, promoted 3. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas
colon carcinogenesis and cell proliferation by interacting A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG. A
with M3 muscarinic receptors that are overexpressed in a randomized trial of rofecoxib for the chemoprevention of colorectal
majority of colon cancers and human colon cancer cells 4. adenomas. Gastroenterology 2006;131:1674-82.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD,
through transactivation of EGFR. [52-55] Although the role Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM,
of FXR as an intestinal tumor suppressor might not be Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn
directly mediated by bile acids, FXR activation can have J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt
tumor-suppressive effects by transcriptional induction RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB,
of detoxifying enzymes that mediate transformation and Hawk ET. Celecoxib for the prevention of sporadic colorectal
excretion of toxic bile acids. Interestingly, FXR’s role 5. adenomas. N Engl J Med 2006;355:873-84.
[51]
Helin-Salmivaara A, Saarelainen S, Gronroos JM, Vesalainen R,
in liver cancer (hepatocellular carcinoma) as a tumor Klaukka T, Huupponen R. Risk of upper gastrointestinal events
suppressor may be mediated by bile acids. [56-59] with the use of various NSAIDs: a case-control study in a general
population. Scand J Gastroenterol 2007;42:923-32.
FUTURE DIRECTIONS 6. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley
A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC.
In addition to being a master regulator of bile acid Rofecoxib and cardiovascular adverse events in adjuvant treatment
of colorectal cancer. N Engl J Med 2007;357:360-9.
synthesis, and glucose and fat metabolism, recent research 7. McGettigan P, Henry D. Cardiovascular risk and inhibition of
data reveal a novel and important role for FXR as a tumor cyclooxygenase: a systematic review of the observational studies
suppressor in intestinal carcinogenesis, cell proliferation of selective and nonselective inhibitors of cyclooxygenase 2.
and tumor growth. Because FXR is considerably down- JAMA 2006;296:1633-44.
regulated in colon tumor cells, restoring or reactivating 8. Modjtahedi H, Essapen S. Epidermal growth factor receptor
FXR expression may offer a therapeutic strategy. In inhibitors in cancer treatment: advances, challenges and opportunities.
Anticancer Drugs 2009;20:851-5.
addition, because normal intestinal epithelial cells express 9. Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal
high levels of FXR, pharmacological FXR agonists cancer. Dis Colon Rectum 2007;50:1259-70.
might be effective chemopreventive agents, particularly 10. Venook AP. Epidermal growth factor receptor-targeted treatment
in high-risk populations, including those with hereditary for advanced colorectal carcinoma. Cancer 2005;103:2435-46.
CRC (e.g. FAP and Lynch syndrome). To avoid systemic 11. Sipples R. Common side effects of anti-EGFR therapy: acneform
rash. Semin Oncol Nurs 2006;22:28-34.
toxicity associated with FXR activation (e.g. 6E-CDCA 12. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp
can cause pruritus) intestine-specific FXR agonists, like LW, van Erpecum KJ. Bile acids and their nuclear receptor FXR:
[60]
fexaramine may be especially useful. [19] relevance for hepatobiliary and gastrointestinal disease. Biochim
Biophys Acta 2010;1801:683-92.
Acknowledgments 13. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a
This work was supported by the office of Research and multipurpose nuclear receptor. Trends Biochem Sci 2006;31:572-80.
Development, Medical Research Service, Department of 14. Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic
regulator and cell protector. Cell Res 2008;18:1087-95.
Veterans Affairs and NIH T32 DK067872 (J. P. Raufman) 15. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG,
and by American Cancer Society Institutional Research Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD,
Grant (G. Xie). Lehmann JM. Bile acids: natural ligands for an orphan nuclear

26
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 1 ¦ January 15, 2016 ¦